UniProtKB/Swiss-Prot P21583: Variant p.Ile148Thr

Kit ligand
Gene: KITLG
Feedback?

Variant information Variant position:

148 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Isoleucine (I) to Threonine (T) at position 148 (I148T, p.Ile148Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and hydrophobic (I) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In WS2F; uncertain significance. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs751013211 [ dbSNP | Ensembl ]

Sequence information Variant position:

148 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

273 The length of the canonical sequence.
Location on the sequence:

KSPEPRLFTPEEFFRIFNRS I DAFKDFVVASETSDCVVSST The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KSPEPRLFTPEEFFRIFNRSIDAFKDF-VVASETSDCVVSST

                              KSPELRLFTPEEFFRIFNRSIDAFKDLETVASKSSECVVSS

Mouse                         KRPETRSFTPEEFFSIFNRSIDAFKDF-MVASDTSDCVLSS

Rat                           KKPETRNFTPEEFFSIFNRSIDAFKDF-MVASDTSDCVLSS

Pig                           KSPEPRLFTPEKFFGIFNRSIDAFKDLEMVAPKTSECVISS

Bovine                        KSPEPRQFTPEKFFGIFNKSIDAFKDLEIVASKMSECVISS

Goat                          KSPEPRQFTPEKFFGIFNKSIDAFKDLEIVASTMSECVISS

Cat                           KSPEPRLFTPEEFFRIFNRSIDAFKDLEMVASKTSECVVSS

Horse                         KSQESRLFTPEEFFRIFNRSIDAFKDLEMVVSKTSECVVSS

Chicken                       HLYEEDRFIPENFFRLFNSTIEVYKEF-ADSLDKNDCIMPS

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	26 – 273	Kit ligand
Chain	26 – 190	Soluble KIT ligand
Topological domain	26 – 214	Extracellular
Glycosylation	145 – 145	N-linked (GlcNAc...) asparagine
Glycosylation	167 – 167	O-linked (GalNAc...) serine
Glycosylation	168 – 168	O-linked (GalNAc...) threonine
Disulfide bond	68 – 163
Helix	137 – 149

Literature citations
Biallelic KITLG variants lead to a distinct spectrum of hypomelanosis and sensorineural hearing loss.
Vona B.; Schwartzbaum D.A.; Rodriguez A.A.; Lewis S.S.; Toosi M.B.; Radhakrishnan P.; Bozan N.; Akin R.; Doosti M.; Manju R.; Duman D.; Sineni C.J.; Nampoothiri S.; Karimiani E.G.; Houlden H.; Bademci G.; Tekin M.; Girisha K.M.; Maroofian R.; Douzgou S.;
J. Eur. Acad. Dermatol. Venereol. 36:1606-1611(2022)
Cited for: VARIANTS WS2F CYS-32; THR-148 AND 215-TRP--VAL-273 DEL; INVOLVEMENT IN WS2F;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.